158 related articles for article (PubMed ID: 10531153)
1. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension.
Wax D; Garofano R; Barst RJ
Chest; 1999 Oct; 116(4):914-20. PubMed ID: 10531153
[TBL] [Abstract][Full Text] [Related]
2. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin.
Barst RJ; Rubin LJ; McGoon MD; Caldwell EJ; Long WA; Levy PS
Ann Intern Med; 1994 Sep; 121(6):409-15. PubMed ID: 8053614
[TBL] [Abstract][Full Text] [Related]
3. [Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension].
Nakayama T; Ishikita T; Matsuura H; Saji T
J Cardiol; 2001 Nov; 38(5):263-71. PubMed ID: 11729726
[TBL] [Abstract][Full Text] [Related]
4. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.
McLaughlin VV; Shillington A; Rich S
Circulation; 2002 Sep; 106(12):1477-82. PubMed ID: 12234951
[TBL] [Abstract][Full Text] [Related]
5. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.
Sitbon O; Humbert M; Nunes H; Parent F; Garcia G; Hervé P; Rainisio M; Simonneau G
J Am Coll Cardiol; 2002 Aug; 40(4):780-8. PubMed ID: 12204511
[TBL] [Abstract][Full Text] [Related]
6. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
[TBL] [Abstract][Full Text] [Related]
7. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
Badesch DB; Tapson VF; McGoon MD; Brundage BH; Rubin LJ; Wigley FM; Rich S; Barst RJ; Barrett PS; Kral KM; Jöbsis MM; Loyd JE; Murali S; Frost A; Girgis R; Bourge RC; Ralph DD; Elliott CG; Hill NS; Langleben D; Schilz RJ; McLaughlin VV; Robbins IM; Groves BM; Shapiro S; Medsger TA
Ann Intern Med; 2000 Mar; 132(6):425-34. PubMed ID: 10733441
[TBL] [Abstract][Full Text] [Related]
8. Sustained improvement of performance and haemodynamics with long-term aerosolised prostacyclin therapy in severe pulmonary hypertension.
Stricker H; Domenighetti G; Fiori G; Mombelli G
Schweiz Med Wochenschr; 1999 Jun; 129(24):923-7. PubMed ID: 10413827
[TBL] [Abstract][Full Text] [Related]
9. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion.
Shapiro SM; Oudiz RJ; Cao T; Romano MA; Beckmann XJ; Georgiou D; Mandayam S; Ginzton LE; Brundage BH
J Am Coll Cardiol; 1997 Aug; 30(2):343-9. PubMed ID: 9247503
[TBL] [Abstract][Full Text] [Related]
10. Effects of continuous intravenous epoprostenol therapy on advanced primary pulmonary hypertension in Taiwanese patients.
Hsu HH; Chen JS; Kuo SH; Chiang FT; Ko WJ; Kuo SW; Huang SC; Lee YC
J Formos Med Assoc; 2005 Jan; 104(1):60-3. PubMed ID: 15660181
[TBL] [Abstract][Full Text] [Related]
11. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
Barst RJ; Rubin LJ; Long WA; McGoon MD; Rich S; Badesch DB; Groves BM; Tapson VF; Bourge RC; Brundage BH; Koerner SK; Langleben D; Keller CA; Murali S; Uretsky BF; Clayton LM; Jöbsis MM; Blackburn SD; Shortino D; Crow JW;
N Engl J Med; 1996 Feb; 334(5):296-301. PubMed ID: 8532025
[TBL] [Abstract][Full Text] [Related]
12. Effects of continuous IV prostacyclin in a patient with pulmonary veno-occlusive disease.
Okumura H; Nagaya N; Kyotani S; Sakamaki F; Nakanishi N; Fukuhara S; Yutani C
Chest; 2002 Sep; 122(3):1096-8. PubMed ID: 12226062
[TBL] [Abstract][Full Text] [Related]
13. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.
Rosenzweig EB; Kerstein D; Barst RJ
Circulation; 1999 Apr; 99(14):1858-65. PubMed ID: 10199883
[TBL] [Abstract][Full Text] [Related]
14. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
15. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.
Humbert M; Sanchez O; Fartoukh M; Jagot JL; Le Gall C; Sitbon O; Parent F; Simonneau G
Eur Respir J; 1999 Jun; 13(6):1351-6. PubMed ID: 10445611
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results].
Jiménez López-Guarch C; Escribano Subias P; Tello de Meneses R; Delgado Jiménez JF; Sadia Pérez D; Velázquez Martín MT; Gómez Sánchez MA; Sáenz de la Calzada C
Rev Esp Cardiol; 2004 Oct; 57(10):946-51. PubMed ID: 15469792
[TBL] [Abstract][Full Text] [Related]
17. [Clinical study on long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol infusion].
Cao TS; Yuan LJ; Duan YY; Wang ZJ; Zhuang L; Shapiro SM; Brundage BH
Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):106-9. PubMed ID: 12783707
[TBL] [Abstract][Full Text] [Related]
18. Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin).
Jones DK; Higenbottam TW; Wallwork J
Br Heart J; 1987 Mar; 57(3):270-8. PubMed ID: 3552006
[TBL] [Abstract][Full Text] [Related]
19. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing.
Miyamoto S; Nagaya N; Satoh T; Kyotani S; Sakamaki F; Fujita M; Nakanishi N; Miyatake K
Am J Respir Crit Care Med; 2000 Feb; 161(2 Pt 1):487-92. PubMed ID: 10673190
[TBL] [Abstract][Full Text] [Related]
20. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
McLaughlin VV; Genthner DE; Panella MM; Rich S
N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
